how can the unique structure of the bispecific abbv-383 impact its safety and efficacy?
Published 1 year ago • 290 plays • Length 4:57Download video MP4
Download video MP3
Similar videos
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
19:49
abbv-383 - upcoming myeloma treatment
-
3:22
updated safety and efficacy results of abbv-383 | ravi vij, md, mba | ash 2023
-
3:23
updated safety and efficacy results of abbv-383, a novel bsab, in patients with r/r multiple myeloma
-
7:44
ash23: abbv-383 bcma x cd3 bispecific antibody for relapsed/refractory myeloma | ravi vij, md, mba
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
14:56
abbvie 383 - guest lecture
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
58:36
bispecific antibodies in multiple myeloma
-
30:24
faqs on bmca-targeted bispecific antibodies in multiple myeloma
-
0:53
what is multiple myeloma?
-
1:27
insights into the phase iii cervino trial: abbv-383 for r/r myeloma
-
0:59
defining the origins of multiple myeloma
-
0:55
what are bispecific antibodies?
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics
-
0:50
what is multiple myeloma: symptoms, treatments & latest clinical trials ?
-
2:19
advances in myeloma treatment
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
4:25
what are the main improvements in next-generation car t-cell products?